All In Biotech

Drug Trial Radar · NCT04625270

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Last checked: Nov 19, 2026Latest source record: Jan 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

225

Planned (sponsor's estimate)

Start

Dec 21, 2020

Primary completion

Nov 15, 2024

Study completion Dec 2026

Sponsor

Lead sponsor
Verastem, Inc.Industry
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
First posted
Nov 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Conditions

  • Low Grade Ovarian Serous Adenocarcinoma
  • Ovarian Cancer

Interventions

  • avutometinib (VS-6766)Drug

    avutometinib (VS-6766) monotherapy

  • avutometinib (VS-6766) and defactinibDrug

    avutometinib (VS-6766) and defactinib combination

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Determine optimal regimen of avutometinib (VS-6766) monotherapy or in combination with defactinibTime frame: From start of treatment to confirmation of response; 24 weeks
  2. Part B: To determine the efficacy of the optimal regimen identified from Part ATime frame: From start of treatment to confirmation of response; 24 weeks
  3. Part C: To evaluate additional efficacy parameters for the optimal regimen identified in Part ATime frame: From start of treatment to confirmation of response; 24 weeks
  4. Part D:To evaluate additional efficacy parameters for a lower dose of avutometinib in combination with defactinibTime frame: From start of treatment to confirmation of response; 24 weeks

Locations

47 sites in 7 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates PC HAL

    Scottsdale, Arizona

  • Sansum Clinic

    Santa Barbara, California

  • Yale School of Medicine

    New Haven, Connecticut

  • Advent Health

    Orlando, Florida

  • H. Lee Moffitt Cancer Center and Research Institute - Center for Women's Oncology

    Tampa, Florida

  • University of Chicago

    Chicago, Illinois

  • Maryland Oncology and Hematology, P.A.

    Glenn Dale, Maryland

  • Minnesota Oncology Hematology PA

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Cleveland Clinic Women's Health Institute

    Cleveland, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • University of Oklahoma Medical Center

    Oklahoma City, Oklahoma

  • Willamette Valley Cancer Institute and Research Center

    Eugene, Oregon

  • Northwest Cancer Specialists

    Portland, Oregon

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Texas Oncology Austin Central

    Austin, Texas

  • Texas Oncology- Dallas Presbyterian Hospital

    Dallas, Texas

  • UT Southwestern Medical Center

    Dallas, Texas

  • Texas Oncology

    Longview, Texas

  • Texas Oncology

    McAllen, Texas

  • Texas Oncology

    San Antonio, Texas

  • Texas Oncology

    The Woodlands, Texas

  • University of Virginia Health System

    Charlottesville, Virginia

  • Virginia Cancer Specialists, PC

    Gainesville, Virginia

  • UZ Gent Medische Oncologie

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • CHU de Liege

    Liège, Belgium

  • Centre de recherche di Centre Hospitalier de i'Universite de Montreal

    Montreal, Canada

  • Princess Margaret Cancer Centre

    Toronto, Canada

  • Hopital Jean Minjoz

    Besançon, France

  • Centre Leon Berard

    Lyon, France

  • ICM - Val d'Aurelle

    Montpellier, France

  • Institut Curie

    Paris, France

  • Insituto Europeo di Oncologia I.R.C.C.S

    Milan, Italy

  • U.O.C. Oncologia 2, Istituto Oncologico Veneto I.R.C.C.S.

    Padova, Italy

  • Hospital Universitario Vall D'Hebron

    Barcelona, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Spain

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.